---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-078622"
form_type: "8-K"
ticker: "SABS"
cik: "0001833214"
company_name: "SAB Biotherapeutics, Inc."
filed_at: "2024-06-27T23:59:59+00:00"
generated_at: "2026-06-01T01:08:16.802852+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# SAB Biotherapeutics shareholders elect directors, approve equity plan amendment, ratify auditor at 2024 annual meeting

## Summary
- Shareholders elected Samuel J. Reich, Christine Hamilton, and Eddie J. Sullivan as Class III directors for three-year terms.
- Approved amendment to 2021 Omnibus Equity Incentive Plan, increasing share reserve by 3.9M to 5.5M shares.
- Ratified EisnerAmper LLP as independent registered public accounting firm for FY 2024.
- Voting results: For director elections, votes ranged from 4.89M to 5.15M with ~1.3M broker non-votes.

## SEC filing metadata
- accession: 0000950170-24-078622
- form_type: 8-K
- ticker: SABS
- cik: 0001833214
- company_name: SAB Biotherapeutics, Inc.
- filed_at: 2024-06-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1833214/000095017024078622/0000950170-24-078622-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1833214/000095017024078622/sabs-20240627.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-078622
- JSON: https://secwatch.observer/filing/0000950170-24-078622.json
- Plain text: https://secwatch.observer/filing/0000950170-24-078622.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.